Live
Endpoints NewsChina biotech’s CRISPR therapy suggests US drugmakers will face competitionBioPharma DiveOricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumorsEndpoints NewsVivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera optionBioPharma DiveRFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degradersEndpoints NewsBiotech VCs ramp up checks on new bets after years of focusing on existing portfoliosAgilentTRADE NEWS: Agilent Technologies and Shimadzu to Exchange Chromatography Instrument Drivers - YahooLonza NewsLonza Group AG stock: What you should know now for smart investing - AD HOC NEWSBioWorldAurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducersBioWorldNew TRPC6/7 antagonists disclosed in Nyrada patentBioWorldBiologics in development outnumber small molecules for the first timeBioWorldRegeneration in mammals is controlled by environmental conditionsFierceBiotechChina’s Oricell raises $110M for carcinoma CAR-T plans ahead of IPO push
BioWorld Apr 10, 2026

Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers

Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers

Original
Body unavailable. Use the original source.

Directory

59 All